REG - Medpal AI PLC - Launch of MedPal Clinic Pharmacy Platform

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251107:nRSG5825Ga&default-theme=true

RNS Number : 5825G  Medpal AI PLC  07 November 2025

7 November 2025

MedPal AI plc

(the "Company" or "MedPal AI")

Launch of MedPal.clinic: UK's First AI-Powered, Multimodal Pharmacy Platform

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on wellness management, is pleased to announce the
launch of MedPal.clinic, its retail pharmacy website, marking a significant
milestone in the Company's mission to make healthcare accessible and
affordable for everyone.

 

The Directors believe that MedPal.clinic represents a UK-first in digital
pharmacy services, combining AI-powered triage with access to qualified
Independent Prescribers ("IPs") and General Practitioners ("GPs"), delivered
through a multimodal communications platform. Users can access clinical
consultations via their preferred communication method, including text
messaging and WhatsApp, providing unprecedented flexibility and convenience in
accessing primary care services.

 

Market Opportunity

 

The MedPal.clinic platform is initially targeting the rapidly expanding UK
weight-loss medication market, specifically GLP-1 agonist treatments, which
represents a significant revenue opportunity. Recent research indicates that
approximately 2.5 million UK adults either currently use or have strong
interest in using GLP-1 drugs for weight loss, with private prescription costs
averaging £150-£200 per month. This represents a target addressable market
exceeding £500 million in monthly revenue within the UK alone.

 

Revolutionary Healthcare Delivery Model

 

MedPal.clinic is powered by the Company's integrated, AI-driven healthcare
ecosystem operating around the clock from its recently opened distribution
centre at Ecotech Business Park, Swaffham. The key advantages of the platform
include:

 

•     Zero-cost consultations: The Company's proprietary AI triage
system assesses patient needs in seconds, fast-tracking routine medication
requests whilst escalating complex cases to qualified IPs and GPs. Advanced AI
triage, combined with robotic dispensing automation, has enabled MedPal to
eliminate consultation fees entirely, providing free access to IPs and GPs
across the UK - a significant differentiator in the market.

 

•     Multimodal access: maximum communication flexibility allowing
patients to engage via text, WhatsApp, or other preferred channels.

 

•     Same-day and next-day delivery: Prescriptions dispensed using
state-of-the-art robotic technology (Omnicell VBM and BD Rowa VMAX systems) at
the Company's automated 24/7 distribution centre, with rapid nationwide
delivery.

 

By combining artificial intelligence, robotic automation, and human clinical
expertise, MedPal.clinic eliminates the traditional bottlenecks in patient
care: long wait times, geographic and access constraints, and high costs.

 

Strategic Integration with MedPal Ecosystem

 

The launch of MedPal.clinic completes the Company's dual-engine business
model:

 

1.   AI-driven wellness app: Data aggregation from over 100 wearables and
health apps, providing personalised non-clinical insights and lifestyle
guidance through the Company's AI wellness coach; and

 

2.   Regulated Distance Selling Pharmacy (DSP): Acquired through the
purchase of assets from Universal Pharmacy Limited (as announced on 1 October
2025), operating from the expanded and automated distribution centre (as
announced on 22 October 2025).

 

This highly complementary flywheel drives demand generation through the
wellness app whilst fulfilling clinical needs through MedPal.clinic's
regulated pharmacy services.

 

Market Positioning and Partnerships

 

The traditional pharmacy model presents challenges for users with regard to
cost, convenience, and accessibility. MedPal.clinic addresses these through
technology-driven efficiency gains and is targetingthe weight-loss medication
market which is experiencing rapid growth in the UK and which is forecast to
grow to more than a billion pound market opportunity in just the coming years.

 

MedPal AI's route-to-market partnerships provide access to 11 million+
eligible employees via Epassi UK Limited and free initial access for members
of 2,000+ gyms through Independent Gyms Ltd, with revenue share arrangements
on post-trial subscriptions. The Company's automated, AI-enhanced
infrastructure delivers superior unit economics compared to traditional
pharmacy models, enabling competitive pricing whilst maintaining clinical
safety and quality standards.

 

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

 

"The launch of MedPal.clinic represents the culmination of our strategic
vision to democratise healthcare access in the UK. By combining our
proprietary AI triage system with advanced robotic dispensing at our Swaffham
facility, we have created a platform that eliminates the financial barrier to
GP and Independent Prescriber consultations entirely - something no other
service has achieved.

 

"Our multimodal approach, allowing patients to communicate via text, WhatsApp,
or their preferred channel, sets a new standard for digital healthcare
accessibility. Coupled with same-day delivery and 24/7 availability,
MedPal.clinic addresses the fundamental failings of the traditional pharmacy
model: cost, convenience, and accessibility.

 

"With our established partnerships providing access to over 13 million
potential users, and the rapidly growing demand for weight-loss medications,
we are well-positioned to capture significant market share whilst delivering
value to patients across the UK."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company take
responsibility for the contents of this announcement.

For further information please visit www.medpalplc.com
(http://www.medpalplc.com) or contact:

 

MedPal AI plc
 
via Square1 Consulting

Jason Drummond, Chief Executive Officer

 

Cairn Financial Advisers LLP
 
+44 20 7213 0880

Louise O'Driscoll/Jo Turner

 

Clear Capital Markets
Limited
+44 20 3869 6080

Bob Roberts/ Nick Josh

 

Square1
Consulting
+44 20 7929 5599

David
Bick
+44 7831 381201

 

 

About MedPal AI

 

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management and regulated online pharmacy services. Its core app
aggregates data from over 100 wearables and health apps (e.g. Apple Health,
Fitbit, Garmin) into a unified profile, offering non-clinical, personalised
lifestyle guidance through its AI wellness coach. The Company is also
developing conversational AI to provide voice-based, real-time health
insights, alerts, and recommendations.

 

Through its wholly owned subsidiary MedPal Limited, the Company operates a
Distance Selling Pharmacy (DSP) licence and a state-of-the-art, AI-powered,
automated distribution centre at Ecotech Business Park, Swaffham, capable of
dispensing over 100,000 prescriptions per month with 24/7 capability.

 

MedPal AI has a partnership agreement with Epassi UK Limited, which grants
access to the MedPal AI app across Epassi's network of 11M+ employees at major
firms like Siemens and Volvo. The Company also has a partnership agreement
with Independent Gyms Ltd, providing access to members of over 2,000 gyms
across the UK. Beyond consumers, MedPal AI plans to expand via B2B licensing
to healthcare providers, businesses, and insurers.

 

Visit our website: www.medpalplc.com (http://www.medpalplc.com)

 

 

Follow us on social media:

X: @MedPalPlc

LinkedIn: MedPal AI plc

 

 

Forward Looking Statements

 

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFLFEALRLRIIE



            Copyright 2019 Regulatory News Service, all rights reserved